Candidate Vaccine Strains and Potency Reagents for Influenza Season

Slides:

Advertisements

Similar presentations

Surveillance in a Pandemic: Situational Awareness

Advertisements

Standards Review Subcommittee Update February 19, 2013.

World Telecommunication Development Conference May to 4 June 2010, Hyderabad, India Programme 1 Resolution 47 Riccardo Passerini Telecommunication.

Practical Blood Bank Lab Adsorption.

1 Building Use Study Plattsburgh City School District Advisory Committee Meeting September 18, 2013 Castallo and Silky- Education Consultants Bill Silky.

Rezoning Study -Community Forum- Thompson Middle School February 15, :30 – 7:30pm.

Biopharmaceutical Quality

18Feb2009VRBPAC Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

FLU SEASON IMPORTANT FACTS.

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

Influenza Vaccine Manufacturing

Influenza Vaccine Considerations Season

FLU SEASON EQ: WHAT YOU SHOULD KNOW FOR THE INFLUENZA SEASON.

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

INFLUENZA DIVISION U.S. Influenza Surveillance Update, Season Joseph Bresee, MD Epidemiology and Prevention Branch, Influenza Division, CDC VRBPAC.

Public Health Impact of Including Two Influenza B Strains in Seasonal Influenza Vaccines Carrie Reed Martin Meltzer Lyn Finelli Anthony Fiore Vaccines.

Item #16 California Measure SB375: Linking Greenhouse Gas Emissions Reductions to Metropolitan Transportation Planning Presentation to the National Capital.

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.

RMP Workshop Objectives Visual, Travel & Special Designations Bureau of Land Management Carlsbad Field Office February 1 st and 2 nd, 2012 Presentation.

Preparation of Reference Influenza Viruses in Mammalian Cells: FDA Perspective Prepared for the Vaccines and Related Biological Products Advisory Committee.

1 ACIP Influenza Vaccine Recommendations Season Carolyn B. Bridges, MD, FACP Associate Director of Adult Immunizations ISD, NCIRD, CDC National.

Lisa Grohskopf, MD, MPH Influenza Division, NCIRD, CDC ACIP Influenza Vaccine Recommendations Season National Center for Immunization & Respiratory.

YES New Mexico Enterprise Eligibility System

Interpreting and Describing Data. General Considerations Correct interpretation depends on your being very familiar with your data –Ongoing process that.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

Overview of SB 191 Ensuring Quality Instruction through Educator Effectiveness Colorado Department of Education Updated: July 2011.

INTRODUCTION TO AP BIOLOGY What is AP Biology  AP Biology is designed to be the equivalent of a University Introductory Biology Course  It.

Doc.: IEEE g Proposed Resolution for Band Specific MR-FSK Radio-Specification July 2010 Seibert (SSN), Jillings (Semtech), Kent.

A model of outhospital management of H1N1v influenza epidemic by SOS Doctors in Greece. Spyridon G. Barbas, MD, Theodore Spiropoulos, MD, George Peppas,MD,

COMMISSION STATISTICS Claims Continue To Decline 2013 – 10, – 11, – 20,557.

1 DELIA MEMORIAL SCHOOL (BROADWAY) New Senior Secondary (NSS) Curriculum

10/10/2013PHY 113 C Fall Lecture 131 PHY 113 C General Physics I 11 AM - 12:15 PM MWF Olin 101 Plan for Lecture 13: Chapter 13 – Fundamental gravitational.

Risk Aversion and Capital Allocation to Risky Assets

DoD Influenza Surveillance and Vaccine Effectiveness Armed Forces Health Surveillance Center (AFHSC) Naval Health Research Center (NHRC) United States.

0 HHS Influenza Vaccine Projects for NVAC Meeting June 7-8, 2005 By: Dr. Robin Robinson (HHS/OPHEP)

Vaccines and Related Biological Products

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE USPHS INFLUENZA VIRUS VACCINE STRAIN SELECTION

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.

1 Licensure of Pandemic Influenza Vaccines: Demonstration of Effectiveness Vaccines and Related Biological Products Advisory Committee Meeting February.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

Expectations for Facilities & cGMPs Biological Response Modifiers Advisory Committee Meeting October 9, 2003 Nicholas Obiri, Ph.D. CBER.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Two: Controlling Animal Influenza.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Options for Influenza Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological.

STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

Seasonal Influenza Therapeutics in Asia- Pacific Markets to 2022-Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent.

Is it Flu? Advances in Diagnostic Strategies and Implications for Patient Care.

Presentation transcript:

Candidate Vaccine Strains and Potency Reagents for 2014-15 Influenza Season Division of Biological Standards & Quality Control Laboratory of Biochemistry, Virology & Immunochemistry OCBQ, CBER, FDA Manju Joshi Prepared for Vaccines and Related Biological Products Advisory Committee 28 February 2014

Influenza A (H1N1) Current Vaccine Strain (2013–14 Season) : A/California/7/2009 (H1N1)pdm09-like virus Reassortants X179A; X181and NIB-74 WHO Recommended Strain for 2014–15: an A/California/7/2009 (H1N1)pdm09-like virus No change from 2013–14 Strain

CBER Authorized Reagents for H1N1 CBER Reference Antigen For Egg Derived X-179A CBER Reference Antigen (Lot 69) (low inventory). X-179A CBER New Reference Antigen (Lot 76: under calibration)* X-181 CBER Reference Antigen (Lot H1-Ag-1107) X-181 Reference Antigen from TGA* NIB-74: Reference Antigen from NIBSC* For Cell Derived A/Brisbane/10/2010 (Cell Derived): Reference Antigen from NIBSC CBER Antibodies New lots: H1-Ab-1304 and H1-Ab-1305 *(CBER approval of these reagents: case by case basis)

Influenza A (H3N2) Current Vaccine Strain (2013–14 Season) : A (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011 A/Texas/50/2012 (reassortants X-223 and X-223 A) WHO Recommended Strain for 2014–15: A/Texas/50/2012 (H3N2)-like virus same as 2013-14 recommendation

CBER Authorized Reagents for H3N2 CBER Reference Antigen For Egg Derived X-223A CBER Reference Antigen (Lot 75) X-223 CBER Reference Antigen (Lot H3-Ag-1308) X-223 Reference Antigen: From NIBSC and NIID* *(CBER approval of these reagents: case by case basis) For Cell Derived X-223A CBER Reference Antigen (Lot H3-Ag-1312) CBER Antibodies New lots: H3-Ab-1314, H3-Ab-1318 and H3-Ab-1319

Influenza B Current Vaccine Strain (2013–14 Season): Yamagata lineage-B/Massachusetts/2/2012-like Virus B/Massachusetts/2/2012 (Wt and Reassortant BX-51B) WHO Recommended Strain for 2014–15: Yamagata lineage-B/Massachusetts/2/2012-like Virus No change from 2013–14 Strain

CBER Authorized Reagents for B-strain (Yamagata Lineage) CBER Reference Antigen For Egg Derived Wild Type CBER Reference Antigen (Lot 74) BX-51B CBER Reference Antigen (Lots B(y)-Ag-1309 & B(y)-Ag-1311) BX-51B-Reference Antigen: From NIBSC and TGA* *(CBER approval of these reagents: case by case basis) For Cell Derived Wild Type CBER Reference Antigen (Lot B(y)-Ag-1313) CBER Antibodies New lots: B(y)-Ab-1315; B(y)-Ab-1316; B(y)-Ab-1321 & B(y)-Ab-1323

Influenza B for Quadrivalent Formulations (2nd B-Strain) WHO Recommended Second B Strain (2013-14 Season): Victoria lineage-B/Brisbane/60/2008-like Viruses. WHO Recommended Second B Strain for 2014-15: Victoria-lineage-B/Brisbane/60/2008-like Viruses No Change from 2013-14 Season

CBER Authorized Reagents for 2nd B-strain (Victoria Lineage) CBER Reference Antigen CBER Reference Antigen (Lot 68): previously used however inventory has been depleted CBER New Reference Antigen (Lot 77: under calibration)* CBER Antibodies Lot B-Ab-1108 (previously used). New Lots: B-Ab-1215 & B-Ab-1216 will be made available Use of Reference Antigen Use of mixture of Reference Antigens for testing of both B Strains in Quadrivalent Vaccine. Correction Factors with use of specific Reference Antigens are not recommended (CBER authorized the use of Antibody Reagents from NIBSC and TGA under special circumstances to gain specificity in quadrivalent testing. Consult with CBER)

Challenges in Production of SRID Reagents Challenges due to selection of multiple reassortant/strains and production of vaccine in different platforms. Homologous Reference Antigen is optimal and preferred; Heterologous Antibodies may be acceptable. If it is not feasible to prepare and calibrate a homologous reagent in the short time frame heterologous reagents may be an option. Performance of heterologous reagents for use in combination with a particular product need to be evaluated. The performance of heterologous reagents need to be verified and authorized by CBER. CBER will work to re-calibrate a heterologous reference antigen if necessary.

CBER Influenza Potency Reagents Summary ….1 CBER authorized reagents should be used to test potency of vaccines marketed in the US. Authorized reagents are either produced by CBER or adopted by CBER for use. CBER collaborates with other ERLs in calibration of adopted reagents. CBER will verify availability and acceptable performance of compatible authorized reagents. The use of reference antigen and reference antiserum (as a calibrated pair) from same source is desirable to avoid discrepancies.

CBER Influenza Potency Reagents Summary….2 Use of same reagents for Monovalent, Trivalent/ Quadrivalent formulations (and follow-up stability studies) for a particular lot is desirable. To confirm Identity of B-strains in Quadrivalent Vaccine: Mono-specific or minimally cross reactive antibodies either developed by CBER or Authorized by CBER are recommended (consult with CBER to receive appropriate Lot) CBER will make every effort to assure timely availability of reagents appropriate for selected vaccine strains. The reagent lots (sp. antisera) may change from those provided last year. Please communicate with CBER and let us know if you have any problem with reagents.

Thank You